Vaccine against Middle East respiratory syndrome coronavirus

Affiliations

¹ Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
² Infectious Diseases Division, Department of Medicine and Department of Research, Prince Mohamed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia; Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
³ Division of Respiratory Medicine and Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Special Administrative Region, China.
⁴ Department of Microbiology and Immunology and Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA. Electronic address: stanley-perlman@uiowa.edu.

Comment

Alimuddin Zumla et al. Lancet Infect Dis. 2019 Oct.

. 2019 Oct;19(10):1054-1055.

doi: 10.1016/S1473-3099(19)30477-3.

¹ Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
² Infectious Diseases Division, Department of Medicine and Department of Research, Prince Mohamed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia; Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
³ Division of Respiratory Medicine and Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Special Administrative Region, China.
⁴ Department of Microbiology and Immunology and Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA. Electronic address: stanley-perlman@uiowa.edu.

No abstract available

Comment on

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN. Modjarrad K, et al. Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24. Lancet Infect Dis. 2019. PMID: 31351922 Free PMC article. Clinical Trial.

1. Modjarrad K, Roberts CC, Mills KT. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19:1013–1022. - PMC - PubMed
1. WHO WHO target product profiles for MERS-CoV vaccines. May, 2017. https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_150...
1. Yoon I-K, Kim JH. First clinical trial of a MERS coronavirus DNA vaccine. Lancet Infect Dis. 2019;19:924–925. - PMC - PubMed
1. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18:e217–e227. - PMC - PubMed
1. Maslow JN. Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus. Hum Vaccin Immunother. 2017;13:2918–2930. - PMC - PubMed